Literature DB >> 3263494

Inhibition of norepinephrine transport into synaptic vesicles by amphetamine analogs.

S M Knepper1, G L Grunewald, C O Rutledge.   

Abstract

The abilities of several amphetamine analogs with restricted conformations to inhibit uptake of [3H]norepinephrine into synaptic vesicles isolated from rat brain cerebral cortex were compared. [3H]Norepinephrine was accumulated in the vesicles with a Km of 3.5 microM and a Vmax of 7.6 pmol/g of tissue per min. This uptake was inhibited by reserpine (IC50, 6.4 nM), amphetamine (IC50, 2.5 microM) and eight amphetamine analogs. 2-Aminotetralin, the most flexible of the analogs (capable of assuming both gauche and anticonformations), was the most potent (IC50, 22 microM). The side chain of amphetamine was held in one of its two low energy conformations [transantiperiplanar (extended) and gauche (folded)]. This was accomplished by using the benzobicyclo[2.2.1]heptane, benzobicylco[2.2.2]octane, or tetrahydroisoquinoline ring systems. The potencies of all of the conformationally defined analogs were reduced with IC50 values of 120 to 370 microM and the potency differences between anti- and gauche conformations were small. These results are in contrast to those obtained by us earlier for inhibition of neuronal reuptake and suggest that vesicular uptake may be more conformationally restrictive than neuronal reuptake. It is possible that: 1) the amphetamine pharmacophore must retain some conformational flexibility for vesicular uptake (hence activity for 2-aminotetralin but not for the rigid analogs); 2) there is another higher energy conformation of amphetamine not present in any of the rigid analogs evaluated that is required for optimal interaction with the vesicular uptake site; or 3) the extra steric bulk of the bridging atoms in the conformational analogs severely interferes with binding at the vesicular uptake site.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263494

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter.

Authors:  S R Jones; R R Gainetdinov; R M Wightman; M G Caron
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

Review 2.  How addictive drugs disrupt presynaptic dopamine neurotransmission.

Authors:  David Sulzer
Journal:  Neuron       Date:  2011-02-24       Impact factor: 17.173

Review 3.  Vesicular neurotransmitter transporters. Potential sites for the regulation of synaptic function.

Authors:  H Varoqui; J D Erickson
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

4.  Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.

Authors:  J D Erickson; M K Schafer; T I Bonner; L E Eiden; E Weihe
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

5.  Assessing Vesicular Monoamine Transport and Toxicity Using Fluorescent False Neurotransmitters.

Authors:  Carlie A Black; Meghan L Bucher; Joshua M Bradner; Lauren Jonas; Kenny Igarza; Gary W Miller
Journal:  Chem Res Toxicol       Date:  2020-12-30       Impact factor: 3.739

6.  A young man with acute dilated cardiomyopathy associated with methylphenidate.

Authors:  Tor-Bjarne Nymark; A Hovland; H Bjørnstad; E W Nielsen
Journal:  Vasc Health Risk Manag       Date:  2008

7.  Methylphenidate has mild hyperglycemic and hypokalemia effects and increases leukocyte and neutrophil counts.

Authors:  Gideon Charach; Eli Karniel; Itamar Grosskopf; Alexander Rabinovich; Lior Charach
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.